People In Brief
This article was originally published in The Gray Sheet
AngioDynamics leadership transition: Eamonn Hobbs, president and CEO of interventional radiology and oncology device maker AngioDynamics, says he will relinquish his role to become vice chairman of the board of directors, once the company has identified a "world class candidate" to lead the company. Hobbs, who co-founded the company 20 years ago, suggests, in a Dec. 3 announcement, that his strengths are primarily "entrepreneurial" and the firm now needs a leader to focus more exclusively on operational and administrative activities. In addition to a CEO, the firm is searching for an executive to manage its oncology/surgery business unit. On Dec. 9, it appointed Michael Sharp, formerly of image-based orthopedics company ConforMIS, as VP of regulatory, quality and clinical affairs
You may also be interested in...
Incoming AngioDynamics CEO Jan Keltjens will draw on his 20-plus years of device industry leadership experience, including as former chief exec of CryoCath Technologies, to shepherd "the next level" of growth at the company
Two CBD marketers warned by FDA in a recent crackdown are targeted in class action complaints alleging they made unsubstantiated health claims and mislabeled ‘illegal drug’ products as supplements. Complaints are a wake-up call to CBD wellness industry to ensure claims are substantiated, as the class action bar is on the prowl following the agency’s 15 warning letter blast in November.
Sign in to continue reading.
Need a specific report?
1000+ reports available
New to Medtech Insight?
Start a free trial today!
Register for our free email digests: